Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × BRAF V600E-mutated /MSS Metastatic Colorectal Cancer × Vemurafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 2 Colorectal Neoplasms 2 Solid Tumor 1 Sarcoma, Clear Cell 1 Relapsed Pediatric Solid Tumor 1 Neoplasms 1 Gastrointestinal Neoplasms 1 Feasibility 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 BRAF V600E-mutated /MSS Metastatic Colorectal Cancer 1

Interventions

camrelizumab 1 Vemurafenib 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05019534 2022-05-19

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

West China Hospital

Phase 1 Unknown

Gastrointestinal

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡